Oral empirical treatment of pneumonia

Preview

Physicians treating community-acquired pneumonia in adults are faced with the challenge of selecting an antimicrobial agent and initiating therapy before a precise cause can be identified. Dr Gleckman discusses factors that can help identify the most likely pathogens, describes advantages and disadvantages of several newer compounds used to treat pneumonia, and outlines an approach to empirical therapy that is based on the patient's age and medical history.

Additional information

Notes on contributors

Richard A. Gleckman

Richard A. Gleckman, MD Dr Gleckman is professor of medicine, Boston University School of Medicine, and director, department of medicine, Carney Hospital, Boston. His research interests include newer antibiotics and geriatric infectious disease.